A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab von O'Connor, Owen A., Deng, Changchun, Amengual, Jennifer Effie, Khalil, Mazen Y., Schreeder, Marshall T., Mahadevan, Daruka, Nikolinakos, Petros, Sawas, Ahmed, Zain, Jasmine M., Patterson, Molly, Moon, Amber, Pauli, Emily K., Cutter, Kathy, Mackenzie, Michelle Ann, Brotherton, Marnie, Hodgson, Jamie, Cooper, Christen N, Sportelli, Peter, Miskin, Hari P., Farber, Charles Michael

Volltext